Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.We conducted CheckMate 577, a […]
» Read more